Eli Lilly and Company
LLY
Pozycja w akcjach
#12
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Cena akcji
$1,256.58
Kapitalizacja rynkowa
$1.183T
Zmiana (1 dzień)
0.02%
Zmiana (1 rok)
58.48%
Kraj
US
Handel Eli Lilly and Company (LLY)
Kategoria
Healthcare
Marża operacyjna dla Eli Lilly and Company (LLY)
Marża operacyjna na dzień February 2026 TTM: 45.56%
Według najnowszych raportów finansowych i ceny akcji Eli Lilly and Company, bieżąca marża operacyjna (TTM) wynosi 45.56%. Na koniec 2024 wynosiła 38.86%.
Historia marży operacyjnej dla Eli Lilly and Company od 2000 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 45.56% | 0.00% |
| 2025 | 45.56% | 17.24% |
| 2024 | 38.86% | 22.94% |
| 2023 | 31.61% | 4.25% |
| 2022 | 30.32% | 8.25% |
| 2021 | 28.01% | -4.66% |
| 2020 | 29.38% | 9.30% |
| 2019 | 26.88% | -4.14% |
| 2018 | 28.04% | 31.77% |
| 2017 | 21.28% | 16.67% |
| 2016 | 18.24% | 1.33% |
| 2015 | 18.00% | 6.07% |
| 2014 | 16.97% | -29.29% |
| 2013 | 24.00% | 8.16% |
| 2012 | 22.19% | -14.69% |
| 2011 | 26.01% | -11.38% |
| 2010 | 29.35% | 0.62% |
| 2009 | 29.17% | 7.52% |
| 2008 | 27.13% | 5.24% |
| 2007 | 25.78% | -1.94% |
| 2006 | 26.29% | 5.54% |
| 2005 | 24.91% | -5.64% |
| 2004 | 26.40% | -5.14% |
| 2003 | 27.83% | -7.36% |
| 2002 | 30.04% | -7.03% |
| 2001 | 32.31% | -1.40% |
| 2000 | 32.77% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 25.70% | -99.44% |
US
|
|
| 29.32% | -99.36% |
US
|
|
| 16.65% | -99.63% |
US
|
|
| 26.59% | -99.42% |
CH
|
|
| 31.24% | -99.31% |
CH
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.